CD44 and neoplasm: Four approaches have been proposed to target CD44: (i) targeting with anti-CD44 antibodies, (ii) interrupting HA-CD44 interaction by HA oligosaccharides (oHAs), (iii) enzymatic degradation of HA, and (iv) tissue-specific deletion of CD44 variant signaling by our validated tissue specific delivery of CD44v6shRNA into tumor cells.